AllSci News
GSK advances dual-antigen mRNA flu vaccine to Phase III after positive Phase II
Positive Phase II data for GSK's mRNA seasonal influenza vaccine candidate FLUm3HA.b-3NA have cleared the bar for a Phase III efficacy trial, with the UK...
Teva's anti-IL-15 antibody cuts gluten-induced intestinal damage in Phase IIa celiac disease trial
A single subcutaneous dose of TEV-'408, Teva Pharmaceutical Industries' (NYSE: TEVA) investigational anti-interleukin-15 monoclonal antibody, significantly...
Raziel's RZL-012 meets Phase III endpoints for submental fat reduction, paving China NDA path
A pivotal 480-patient Phase III trial of utenpanium chloride (RZL-012) has met all primary and secondary efficacy and safety endpoints in submental fat (fat...
Vertex closes USD 10b Crinetics deal to establish endocrinology as fifth therapeutic pillar
Vertex Pharmaceuticals (Nasdaq: VRTX) completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, adding a commercially launched rare...
BigHat's AI-designed CDH17 antibody enters human testing for gastric cancer
San Mateo, California-based BigHat Biosciences has dosed its first patient with BHB810, a cadherin-17 (CDH17)-directed antibody-drug conjugate (ADC) for...
Ono Pharma taps Aitia's causal AI to identify neurological disease targets
Ono Pharmaceutical Co., Ltd. and Cambridge, Massachusetts-based Aitia, Inc. have announced a drug discovery partnership covering neurological diseases,...
Evotec and Plectonic combine T-cell platforms to tackle solid tumor selectivity challenge
Combining two preclinical platform technologies that each address a distinct failure mode of T-cell engager therapy in solid tumors, Evotec SE (Nasdaq: EVO)...
FDA grants breakthrough status to Juniper hypoxia tracer for radiation de-escalation in HPV-positive OPC
Bedminster, New Jersey-based Juniper Biosciences announced receipt of US FDA Breakthrough Therapy Designation (BTD) for JBS-003 (18F-fluoromisonidazole, or...
Ocugen launches Phase III trial of one-time gene therapy for geographic atrophy
Ocugen (Nasdaq: OCGN) has dosed the first patient in ArMaDa3, a global Phase III registrational trial of OCU410, an AAV5-based modifier gene therapy for...
Envudeucitinib misses Phase IIb lupus endpoints, subgroup signal keeps program alive
The Phase IIb LUMUS trial of envudeucitinib in systemic lupus erythematosus (SLE) failed to meet its primary and secondary endpoints in the overall patient...
Novartis's remibrutinib beats teriflunomide across Phase III relapsing MS trials
Novartis's remibrutinib has met the primary endpoint in both replicate Phase III trials in relapsing multiple sclerosis (RMS), demonstrating superiority...
BioNTech halts personalized mRNA cancer vaccine trial in CRC after survival imbalance
BioNTech SE (Nasdaq: BNTX) has terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer after an independent data safety...
10x wins USD 4.8m willful-infringement verdict against Qiagen-owned Parse
A federal jury in the US District Court for the District of Delaware has found that Parse Biosciences — now a subsidiary of Netherlands-based Qiagen (NYSE:...
Savolitinib plus Tagrisso hits first-line PFS goal in MET-overexpressing EGFR-mutated lung cancer
The SANOVO Phase III trial has moved savolitinib (Orpathys) plus osimertinib into the first-line EGFR-mutated lung cancer setting, showing a statistically...
Convergen raises USD 15m to advance tau-targeting protein degradation platform
Suzhou-based Convergen has closed a USD 15 million Seed+ financing round to advance its TrimTAC targeted protein degradation platform for neurodegenerative...
The AllSci Brief
Free, systematic R&D and deal news. Daily.